Chronic Venous Insufficiency (CVI)
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
InterVeneCA - Redwood City
1 programBlueLeaf® Endovenous Valve Formation SystemN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Pierre FabreV0322 BC
InterVeneBlueLeaf® Endovenous Valve Formation System
Clinical Trials (2)
Total enrollment: 107 patients across 2 trials
Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema
Start: Jan 2011Est. completion: Mar 201292 patients
Phase 3Completed
Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System (INFINITE-US)
Start: Feb 2020Est. completion: Sep 202315 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.